In response to "who are the 10%? - Non eligibility of cystic fibrosis (CF) patients for highly effective modulator therapies".

McGarry, Meghan E; McColley, Susanna A; Taylor-Cousar, Jennifer

McGarry, Meghan E; McColley, Susanna A; Taylor-Cousar, Jennifer.

Afiliación

McGarry ME; Department of Pediatrics, University of California San Francisco, United States. Electronic address: meghan.mcgarry@ucsf.edu.
McColley SA; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, United States.
Taylor-Cousar J; Department of Medicine and Pediatrics, National Jewish Health, United States.

Respir Med ; 202: 106953, 2022 10.

Article en En | MEDLINE | ID: mdl-36049345

Asunto(s)

Fibrosis Quística; Aminofenoles/uso terapéutico; Fibrosis Quística/tratamiento farmacológico; Regulador de Conductancia de Transmembrana de Fibrosis Quística/genética; Humanos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrosis Quística Límite: Humans Idioma: En Revista: Respir Med Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google